ARTICLE | Targets & Mechanisms

Viral boost for cancer immunotherapies

June 30, 2011 7:00 AM UTC

Researchers at Hannover Medical School and District Clinics Reutlingen have used oncolytic viruses to break immune tolerance toward tumor cells and thus boost the efficacy of dendritic cell-based cancer vaccines.1 The group is now evaluating whether virus-induced tumor inflammation could bolster the efficacy of other classes of cancer immunotherapies.

Immune tolerance toward tumor cells and the low inherent immunogenicity of many tumor-associated antigens make it difficult to stimulate a robust antitumor immune response and can limit the efficacy of cancer immunotherapies...